Option chain shows key data for Pyxis Tankers's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Pyxis Tankers.

Pyxis Tankers (NASDAQ:PXS) Stock, Option Chain

Pyxis Tankers

Pyxis Tankers Inc is an international maritime transportation company that focuses on the product tanker sector. It owns a fleet that comprises double-hull product tankers employed under a mix of short- and medium-term time charters and spot charters. The fleet owned by the company includes Pyxis Epsilon, Pyxis Theta, Pyxis Malou, Northsea Alpha, and Northsea Beta. Each of the vessels in the fleet is capable of transporting refined petroleum products, such as naphtha, gasoline, jet fuel, kerosene, diesel, fuel oil, and other liquid bulk items, such as vegetable oils and organic chemicals.

Riding The Rotation To Industrials And Materials

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

HSHP

SBLK

Top 3 Industrials Stocks You&#39;ll Regret Missing In December

Penny Stocks

Capital Link President Nicolas Bornozis recently hosted an interview with Mr. Eddie Valentis, Chairman &amp; CEO of Pyxis Tankers Inc. (NASDAQ: PXS).

Pyxis Tankers – Continued Focus On Shareholder Returns With Diversification Into The Dry Bulk Sector

Small Cap

Movers

AIXI

AMST

AVAV

BFLY

BFRG

CDAK

CDLX

CMND

DNMR

FRGT

GATO

GCTK

GFAI

GOCO

GROV

HCDI

IDAI

IMBI

KRBP

LNZA

MARK

MDJH

MGOL

MGRX

NFTG

NOGN

ONCT

PLXP

PYXS

SECO

SPCE

VBIV

VORB

WTER

Gainers


	Secoo Holding Limited (NASDAQ: SECO) shares surged 138% to $1.43.


Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Pyxis Tankers Inc

Pyxis Tankers Inc 7.75% PRF PERPETUAL USD 25 - Ser A

PHOENIX MEDIA INV NEW by PHOENIX MEDIA INVT (HOLDINGS) LTD.

Phoenix Media Investment (Holdings) Ltd

Guidance

TGLS

Tecnoglass Introducing FY025 Outlook For Revenues Of $940M - $1.02B (Est $979.975M), Representing Growth Of 10% At Midpoint Of Range

Wells Fargo analyst Ken Gawrelski maintains eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) with a Equal-Weight and raises the price target from $61 to $64.

Price Target

Analyst Ratings

EBAY

Wells Fargo Maintains Equal-Weight on eBay, Raises Price Target to $64

Macerich (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) reported quarterly earnings of $0.47 per share which beat the analyst consensus estimate of $0.46 by 2.17 percent. This is a 16.07 percent decrease over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $273.68 million which beat the analyst consensus estimate of $223.10 million by 22.67 percent. This is a 14.66 percent increase over sales of $238.69 million the same period last year.

Earnings

Earnings Beats

Macerich Q4 FFO $0.47 Beats $0.46 Estimate, Sales $273.68M Beat $223.10M Estimate

Vistra Reaffirmed Guidance For 2025 Ongoing Operations Adjusted EBITDA Of $5.5B To $6.1B

Key Preclinical Findings on AEX-2 (20 mg/kg, IP)
Recent preclinical advancements have demonstrated the multi-target potential of DOXA compounds, including AEX-41 and AEX-2, in redefining sleep-wake regulation and neuroprotection. In orexin-deficient mouse models, these compounds exhibited strong wake-promoting effects and sleep-wake cycle stabilization, reinforcing their potential as next-generation therapeutics. Key findings include:
<ul>
<li>Wakefulness Enhancement: AEX-2 significantly increased total wake duration while maintaining a stable wake architecture, avoiding excessive fragmentation.</li>
<li>REM Sleep Preservation: Unlike traditional stimulants, AEX-2 regulated rapid eye movement ("REM") sleep dynamics, minimizing undesired suppression and sleep rebound effects.</li>
<li>Reduction in Cataplexy: AEX-2 effectively reduced the frequency and duration of cataplexy episodes, a crucial advancement for treating narcolepsy type 1 (NT1).</li>
</ul>
These data underscore the potential of AEX-2 as a safer and more targeted alternative to existing orexin-based therapies, such as TAK-994 and TAK-861, which have been hindered by safety concerns.
Expanding the AEX Platform: AEX-2 and AEX-41 in Neurodegeneration and Metabolic Disorders
Beyond narcolepsy, NLS Pharmaceutics and Aexon Labs are advancing AEX-2 and AEX-41 into new therapeutic areas, leveraging their multi-target mechanisms that extend to neuroinflammatory and metabolic pathways.
<ul>
<li>Targeting&nbsp;Neuroinflammation: Recent discoveries highlight AEX compounds' engagement with the Sigma-1 receptor, which plays a key role in neuroprotection, synaptic plasticity, and REM sleep regulation.</li>
<li>Potential in ALS and Neurodegenerative Diseases: Sigma-1 receptor modulation, combined with orexin receptor activation, suggests AEX-41 may have applications in ALS and Parkinson's disease, particularly in preserving motor function and reducing neuroinflammation.</li>
<li>Addressing Diabetes-Associated Neurological Disorders ("DANS"): Given the link between orexin signalling, metabolic regulation, and sleep disorders, the multi-target properties of DOXA compounds such as AEX-2 and AEX-41 could provide new therapeutic avenues for diabetes-related neuropathy and cognitive decline.</li>
</ul>
Aexon Labs, known for its cutting-edge computational chemistry and AI-driven drug discovery, has played a key role in optimizing these multi-target molecules, ensuring high blood-brain barrier penetration and selective receptor affinity

Biotech

Health Care

General

NLSP

NLS Pharmaceutics In Collaboration With Aexon Labs Announced New Preclinical Findings On Aex-2 For Narcolepsy And Related Neurological Disorders

Palmer Square Capital BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSBD#NYSE">PSBD</a>) reported quarterly earnings of $0.45 per share which met the analyst consensus estimate. This is a 22.41 percent decrease over earnings of $0.58 per share from the same period last year. The company reported quarterly sales of $34.87 million which beat the analyst consensus estimate of $34.86 million by 0.04 percent. This is a 16.93 percent increase over sales of $29.82 million the same period last year.

PSBD

Palmer Square Capital BDC Q4 GAAP EPS $0.45, Inline, Sales $34.87M Beat $34.86M Estimate

Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.34) by 2.94 percent. This is a 9.37 percent decrease over losses of $(0.32) per share from the same period last year. The company reported quarterly sales of $4.12 million which missed the analyst consensus estimate of $7.77 million by 46.99 percent. This is a 24.19 percent decrease over sales of $5.43 million the same period last year.

Earnings Misses

TNGX

Tango Therapeutics Q4 2024 GAAP EPS $(0.35) Misses $(0.34) Estimate, Sales $4.12M Miss $7.77M Estimate

Scholar Rock Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.60) by 1.67 percent. This is a 22 percent decrease over losses of $(0.50) per share from the same period last year.

SRRK

Scholar Rock Holding Q4 EPS $(0.61) Misses $(0.60) Estimate

WIIM

Freeport-McMoRan shares are trading higher after Jefferies upgraded the stock from Hold to Buy and raised its price target from $40 to $48.

PureCycle Technologies Restricted & Unrestricted Cash Stood At $41.5M As Of Dec 31, 2025

Hayward Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) sees FY2025 sales of $1.060 billion-$1.100 billion vs $1.08 billion analyst estimate.

HAYW

Hayward Holdings Sees FY2025 Sales $1.060B-$1.100B vs $1.08B Est

Business Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">First Quarter 2025 Guidance</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Full-Year 2025 Guidance</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$130 – 133 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$555 – 570 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Year-over-year revenue growth (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">29</td>
<td colspan="1" rowspan="1">%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">17</td>
<td colspan="1" rowspan="1">%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA (2)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$28 – 30 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$132 – 138 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA margin (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">22</td>
<td colspan="1" rowspan="1">%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">24</td>
<td colspan="1" rowspan="1">%</td>
</tr>
</tbody>
</table>
</figure>

OPRA

Opera Expects Q1 Revenue Of $130M-$133M Vs $121.45M Est, FY25 Revenue Of $555M-$570M Vs $547.10M Est

Hayward Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.24 by 12.5 percent. This is a 35 percent increase over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $327.07 million which beat the analyst consensus estimate of $302.77 million by 8.03 percent. This is a 17.45 percent increase over sales of $278.47 million the same period last year.

Hayward Holdings Q4 Adj EPS $0.27 Beats $0.24 Estimate, Sales $327.07M Beat $302.77M Estimate

Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.67) by 104.48 percent. This is a 110.34 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $37.40 million which beat the analyst consensus estimate of $13.12 million by 185.04 percent. This is a 10.63 percent decrease over sales of $41.85 million the same period last year.

TRDA

Entrada Therapeutics Q4 2024 GAAP EPS $0.03 Beats $(0.67) Estimate, Sales $37.40M Beat $13.12M Estimate

MRNA

Moderna shares are trading lower following reports suggesting officials in the Trump administration are reconsidering $590 million in funding for the company's bird flu vaccine.

The shipment features Pink Kush, the top-selling dried flower strain over the past four years in Canada.

Cannabis

Village Farms International Announced Its First Shipment To New Zealand Through Its Wholly-owned Subsidiary Pure Sunfarms

Company Initiates 2025 Guidance
Kimbell is providing financial and operational guidance ranges for 2025 as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="3" rowspan="1">Kimbell Royalty</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="3" rowspan="1">Partners LP</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">2025</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Production - Mboe/d (6:1)&nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">24.0</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">27.0</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Oil Production - % of Net Production</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">31&nbsp;%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">35&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Natural Gas Production - % of Net Production</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">46&nbsp;%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">50&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Natural Gas Liquids Production - % of Net Production</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">17&nbsp;%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">21&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Unit Costs ($/boe)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Marketing and other deductions</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1.40</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$2.20</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation and depletion expense</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$13.00</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$20.00</td>
</tr>
<tr>
<td colspan="1" rowspan="1">G&amp;A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp; Cash G&amp;A&nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$2.45</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$2.65</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp; Non-Cash G&amp;A</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$1.40</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">$1.80</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Production and ad valorem taxes - % of Oil, Natural Gas and NGL Revenues</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">7.0&nbsp;%</td>
<td colspan="1" rowspan="1">-</td>
<td colspan="1" rowspan="1">9.0&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Payout Ratio (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">75&nbsp;%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Kimbell Royalty Partners 2025 Guidance: Projects Daily Production Between 24,000 Boe/d - 27,000 Boe/d

Wells Fargo initiates coverage on HASI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HASI#NYSE">HASI</a>) with a Overweight rating and announces Price Target of $33.

Initiation

Hannon Armstrong Sustainable Infrastructure Capital

HASI

Wells Fargo Initiates Coverage On HASI with Overweight Rating, Announces Price Target of $33

J.M. Smucker Raises FY25 Adj EPS Guidance From $9.70 - $10.10 To $9.85 - $10.15 Vs. $10.47 Est.

Sotera Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHC#NASDAQ">SHC</a>) is looking for FY2025 Adj EPS of $0.70-$0.76 vs $0.78 analyst estimate. sees sales of $1.144 billion-$1.166 billion vs $1.16 billion analyst estimate.

Sotera Health Sees FY2025 Adj EPS $0.70-$0.76 vs $0.78 Est; Sees net revenues growth outlook of 4.0% - 6.0% YOY  $1.144B-$1.166B vs $1.16B Est

Press Releases

Pyxis Tankers Announces Joint Venture Agreement to Acquire Modern Dry-Bulk Vessel,  Expansion of Common Share Repurchase Program & Partial Redemption of Series A Cumulative Convertible Preferred Stock

Pyxis Tankers chairman and CEO on market outlook and growth strategies

Pyxis Tankers Announces Closing of Modern Dry Bulk Vessel Joint Venture

Pyxis Tankers Announces Date for the Release of the Second Quarter 2024 Results and Related Conference Call & Webcast

Pyxis Tankers Announces Financial Results for the Three Months Ended June 30, 2024

Pyxis Tankers Announces Full Redemption of Series A Convertible Preferred Stock and Updates on Common Share Repurchase Program & Chartering Activity

Pyxis Tankers to Present at the 2024 ThinkEquity Conference

Pyxis Tankers Announces Date for the Release of the Third Quarter 2024 Results and Related Conference Call & Webcast

Pyxis Tankers Announces Financial Results for the Three Months Ended September 30, 2024

Pyxis Tankers Announces Completion of Common Share Repurchase Program &  Update on Chartering Activity

Capital Clean Energy Carriers Corp. - Common Share

Capital Clean Energy

Costamare Inc. Common Stock $0.0001 par value

Costamare

Castor Maritime

Danaos

Diana Shipping

EuroDry

Euroseas

Globus Maritime

Genco Shipping & Trading Limited Ordinary Shares New (Marshall Islands)

Genco Shipping & Trading

Golden Ocean Group Limited - Common Stock

Golden Ocean Group

Global Ship Lease Inc New Class A Common Shares

Global Ship Lease

Himalaya Shipping

High-Trend International Group - Class A Ordinary Shares

High-Trend International

Kirby

Lakeside Holding

Matson

Navios Maritime Partners LP Common Units Representing Limited Partner Interests

Navios Maritime Partners

Pangaea Logistics Solutions Ltd. - Common Stock

Pangaea Logistics Solns

Performance Shipping Inc. - Common Shares

Performance Shipping

Safe Bulkers, Inc Common Stock ($0.001 par value)

Safe Bulkers

Star Bulk Carriers

Seanergy Maritime Holdings Corp. - Common Stock

Seanergy Maritime Hldgs

Toro

United Maritime Corporation - Common Stock

United Maritime

ZIM Integrated Shipping Services Ltd. Ordinary Shares

Comments

Pyxis Tankers

Pyxis Tankers (PXS) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga